Try our beta test site
57 studies found for:    Small Cell Cancer of the Bladder | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Condition: Bladder Cancer
Interventions: Radiation: Prophylactic Cranial Irradiation (PCI);   Other: Brain X-ray
2 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
3 Recruiting A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cobimetinib
4 Not yet recruiting Alisertib in Chemotherapy-pretreated Urothelial Cancer
Conditions: Bladder Cancer;   Transitional Cell Carcinoma
Interventions: Drug: Alisertib;   Drug: Paclitaxel;   Drug: Placebo
5 Not yet recruiting sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
Conditions: Infiltrating Bladder Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage I Prostate Cancer;   Stage I Renal Cell Cancer;   Stage II Bladder Urothelial Carcinoma;   Stage II Renal Cell Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Radical Cystectomy;   Biological: Recombinant EphB4-HSA Fusion Protein;   Procedure: Therapeutic Conventional Surgery
6 Recruiting A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Condition: Neoplasms
Intervention: Drug: JNJ-63723283
7 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
8 Recruiting Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Conditions: Prostate Cancer;   Bladder Cancer;   Kidney Cancer
Intervention: Drug: Ferumoxytol
9 Not yet recruiting Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Conditions: Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Procedure: Radical Cystectomy;   Biological: Tumor Cell-Derived Vaccine Therapy
10 Recruiting Study of Tumour Focused Radiotherapy for Bladder Cancer
Condition: Bladder Cancer
Interventions: Radiation: WBRT;   Radiation: SART;   Radiation: DART
11 Not yet recruiting Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer
Condition: Stage II Bladder Urothelial Carcinoma
Interventions: Procedure: Catheter Management;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
12 Recruiting Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
Condition: Solid Tumors
Interventions: Drug: NC-6004;   Drug: Gemcitabine
13 Recruiting Tranexamic Acid During Cystectomy Trial (TACT)
Condition: Bladder Cancer
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
14 Recruiting A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Conditions: Urinary Bladder Cancer;   Bladder Tumors;   Transitional Cell Carcinoma of the Bladder;   Malignant Melanoma;   Melanoma;   Skin Cancer;   Carcinoma, Non-Small-Cell Lung;   Lung Cancer
Interventions: Biological: NEO-PV-01;   Biological: Nivolumab;   Other: Adjuvant
15 Recruiting Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Conditions: Recurrent Bladder Urothelial Carcinoma;   Stage 0a Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Cancer With Carcinoma In Situ;   Stage I Bladder Urothelial Carcinoma
Interventions: Drug: Atezolizumab;   Other: Laboratory Biomarker Analysis
16 Recruiting Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
Condition: Urothelial Bladder Carcinoma
Intervention: Drug: Pembrolizumab (MK-3475)
17 Not yet recruiting Functional Outcomes Following Anal Cancer Treatment
Condition: Anal Cancer
Intervention:
18 Recruiting A Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study)
Condition: Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
Intervention: Drug: Trastuzumab Emtansine
19 Recruiting Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Conditions: Metastatic Ureteral Neoplasm;   Metastatic Urethral Neoplasm;   Stage III Bladder Urothelial Carcinoma;   Stage III Ureter Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Ureter Cancer;   Stage IV Urethral Cancer;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
Interventions: Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride
20 Recruiting Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Conditions: Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
Interventions: Drug: 75 approved agents;   Other: COXEN

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.